Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribocytokine IL-7 BNT152
- Development stage
- Phase 1
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
BNT152 is a nucleoside-modified messenger RNA (mRNA) drug formulated in lipid nanoparticles (LNPs), encoding the endogenous cytokine interleukin-7 (IL-7). It is designed as an immunostimulant for cancer therapy, specifically targeting advanced solid tumors that are metastatic or unresectable. The mRNA instructs cells to produce IL-7, a cytokine known to stimulate immune cell proliferation and function, thereby enhancing anti-tumor immune responses. Developed by BioNTech, BNT152 is currently being evaluated in Phase 1 clinical trials as both monotherapy and in combination with other agents for patients with various solid malignancies who have no standard treatment options likely to confer benefit[1][2][3][5].
- Other names
- ribocytokine IL-7 BNT152
02
Targets
IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on ribocytokine IL-7 BNT152.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribocytokine IL-7 BNT152.